Corporate News. May 10, 2012 STADA The Health Company Page 1 of 9
|
|
- Alexandrina Hill
- 6 years ago
- Views:
Transcription
1 Corporate News STADA: Excellent start in Q1/2012 Increase in all adjusted key earnings figures Reported key earnings figures burdened by planned one-time special effects Positive outlook until 2014 confirmed Important items at a glance Sales development in 1-3/2012 within expectations Profitability further increased Gross margin rises to over 50%: Group sales EUR million (+6%) Net income EUR 19.4 million (-35% adjusted +18%) EBITDA EUR 77.3 million (-3% adjusted +12%) Earnings per share EUR 0.33 (-35% adjusted +20%) Expansion of international business activities to 72% of Group sales Cash flow from operating activities increases to EUR 46.1 million (+9%) Due to the implementation of the cost efficiency program STADA build the future, planned burdening one-time special effects in the amount of EUR 18.9 million before tax Integration of acquired business activities according to plan Positive outlook for 2012 confirmed: further growth in Group sales and the opportunity for an increase of adjusted EBITDA in the high single-digit percent area long-term targets for 2014 affirmed Bad Vilbel, May 10, 2012 Today, on May 10, 2012, STADA Arzneimittel AG published the financial results for the first quarter of Accordingly, Group sales as well as all operational, i.e. adjusted for one-time special effects, key earnings figures increased. In view of the largely planned, burdening one-time special effects, which were particularly attributable to the further implementation of the Group-wide cost efficiency program STADA build the future, the reported key earnings figures recorded an expected decrease in the reporting quarter. May 10, 2012 STADA The Health Company Page 1 of 9
2 Overall, STADA's business development was operationally good in the first quarter of Adjusted for largely planned, burdening one-time special effects, EBITDA and net income even met our highest expectations, according to Hartmut Retzlaff, Chairman of the Executive Board of STADA Arzneimittel AG. In addition, we made significant progress in the context of our accelerated acquisitions policy to complement our organic growth. The integration of business activities that we have just recently acquired is also progressing according to plan, said Retzlaff, satisfied with the successful progress of integration management. Development of Sales In the first three months of 2012, Group sales increased by 6% to EUR million (1-3/2011: EUR million). The increase continued to be attributable to growth in STADA s international sales, whose share in Group sales in the reporting quarter totaled 72% (1-3/2011: 70%) and recorded growth of 10% to EUR million (1-3/2011: EUR million). In consideration of sales influences, which are based on changes in the Group portfolio and currency effects, Group sales recorded growth of 2% in the reporting period as compared with the corresponding period of the previous year. Sales of Generics, which continues to be the clearly larger core segment, recorded an increase of 2% to EUR million (1-3/2011: EUR million) in the first quarter of Generics thus contributed 67.5% to Group sales in the reporting period (1-3/2011: 70.0%). Adjusted, generics sales in the Group increased by 1%. The Branded Products core segment recorded growth in sales of 18% to EUR million in the first three months of the current financial year (1-3/2011: EUR million). Branded Products thus had a share of 30.5% in Group sales in the first quarter of 2012 (1-3/2011: 27.4%). The Group recorded growth of 6% in adjusted sales of branded products. The main focus of STADA's business activities continued to be clearly on Europe in the reporting period. Here, STADA Group sales increased by 6% to EUR million (1-3/2011: EUR million) in the first quarter of In Western Europe, STADA May 10, 2012 STADA The Health Company Page 2 of 9
3 recorded an increase in sales in the first three months of 2012 of 4% to EUR million (1-3/2011: EUR million). In Eastern Europe, STADA achieved a sales increase of 11% to EUR million in the reporting quarter (1-3/2011: EUR million). Earnings development The earnings development in the first quarter of 2012 was characterized by an increase in operating performance that was shown with growth in all of the Group s operational, i.e adjusted for one-time special effects, key earnings figures. The reported key earnings figures, however, recorded a decline, which was attributable to the burdening one-time special effects, in particular from the further planned implementation of the Group-wide cost efficiency program STADA build the future. Reported operating profit thus declined in the first three months of 2012 by 20% to EUR 46.3 million (1-3/2011: EUR 57.6 million). Reported net income reduced by 35% to EUR 19.4 million (1-3/2011: EUR 29.8 million) in the reporting quarter. Reported EBITDA showed a decrease of 3% to EUR 77.3 million in the first quarter of 2012 (1-3/2011: EUR 79.8 million). After adjusting the key earnings figures for influences distorting the period comparison resulting from one-time special effects and non-operational effects from interest rate hedge transactions, adjusted operating profit recorded growth of 7% to EUR 67.9 million (1-3/2011: EUR 63.6 million) in the first three months of Adjusted net income recorded growth of 18% to EUR 39.3 million (1-3/2011: EUR 33.2 million) in the reporting period. Adjusted EBITDA increased in the first three months of the current financial year by 12% to EUR 92.3 million (1-3/2011: EUR 82.5 million). Adjusted net income and adjusted EBITDA thus met the highest expectations of the Executive Board. One-time special effects recorded a net burden on earnings of EUR 21.6 million before or EUR 20.0 million after taxes in the first quarter of 2012 (1-3/2011: net burden on earnings due to one-time special effects in the amount of EUR 5.9 million before or EUR 4.5 million after taxes). Non-operational effects from interest rate hedge May 10, 2012 STADA The Health Company Page 3 of 9
4 transactions amounted, in the first quarter of 2012, to a net relief on earnings of EUR 0.1 million before or EUR 0.1 million after taxes, which resulted from the measurement of these transactions (1-3/2011: net relief on earnings as a result of non-operational effects from interest rate hedge transactions of EUR 1.5 million before or EUR 1.1 million after taxes). Taking into account these adjustments resulted in the following development of the reported and adjusted key earnings figures in the first quarter of 2012: in EUR million 1-3/ /2011 +/- Operating profit % Operating profit, adjusted % EBITDA (earnings before interest, taxes, depreciation and amortization) % EBITDA, adjusted % EBIT (earnings before interest and taxes) % EBIT, adjusted % EBT (earnings before taxes) % EBT, adjusted % Net income % Net income, adjusted % Earnings per share in EUR % Earnings per share in EUR, adjusted % May 10, 2012 STADA The Health Company Page 4 of 9
5 Balance sheet and cash flow As of the reporting date March 31, 2012, the equity-to-assets ratio was 30.6% (December 31, 2011: 30.9%) and thereby satisfactory in the opinion of the Executive Board. Against the backdrop of the very high payments in the first quarter for the acquisition of companies and products for the expansion of the portfolio in the short term in the total amount of EUR million (1-3/2011: EUR 1.1 million), net debt rose to EUR 1,217.0 million as of March 31, 2012 (December 31, 2011: EUR million). The net debt to adjusted EBITDA ratio amounted in the first quarter of 2012 on linear extrapolation of the adjusted EBITDA of the first quarter on a full year basis to 3.3 (1-3/2011: 2.5) and was thus, as expected in view of these recently made acquisitions, above the maximum value of 3 strived for by the Executive Board. The Executive Board still aims to once again reduce this figure to a maximum value of 3 within a period of 12 to 18 months. Free cash flow in the first quarter of the current financial year was at EUR million resulting from cash flow from investing activities characterized by the high payments for investments (1-3/2011: EUR 31.2 million). Free cash flow adjusted for payments for significant acquisitions and proceeds from significant disposals amounted to EUR 30.4 million in the reporting quarter (1-3/2011: EUR 32.4 million). With growth of 12% in adjusted EBITDA, we have had an excellent start in the new financial year despite continuing difficult market conditions in Germany and the conversion of the distribution model in Serbia which temporarily curb sales. In addition to ongoing improvement in margins, a particular highlight is the positive trend in operating cash flow, among other things, supported by an improved credit management and an optimized cost structure in Serbia. The implementation of our efficiency program STADA build the future is moving ahead according to plan, said Helmut Kraft, STADA's Chief Financial Officer. May 10, 2012 STADA The Health Company Page 5 of 9
6 Regional development in STADA s two largest national markets STADA's two largest national markets remained Germany and Russia in the reporting quarter. In Germany, the largest national market for STADA, sales in the reporting period decreased by 4% to EUR million (1-3/2011: EUR million). Overall, STADA s German business activities contributed 27.7% to Group sales in the first three months of 2012 (1-3/2011: 30.4%). The decrease in sales was still attributable to the difficult local framework conditions for generics, which are characterized by intensive competition for tenders for discount agreements with public health insurance organizations. In view of this, sales in the German Generics segment in the first three months of 2012 recorded a decrease of 6% to EUR 87.0 million (1-3/2011: EUR 92.5 million). Sales generated by STADA in the German market with generics in the reporting period amounted to 71% (1-3/2011: 73%) of total sales generated in the German market. Sales generated with branded products recorded growth of 3% in the first three months of 2012 to EUR 35.5 million (1-3/2011: EUR 34.5 million). Sales achieved by STADA in Germany with branded products had a total share of 29% (1-3/2011: 27%) of sales generated in the German market. For financial year 2012, the Executive Board still expects the German business has a moderate chance for growth on the whole with operating profitability continuing at only just under the Group average. In view of partly high-volume discount agreements concluded in 2011, the STADA Executive Board expects that the Group's market share by volume will continue to grow in the German generics market. In Russia, the Group s second most important national market according to sales, sales increased in the first quarter of 2012 by a strong 16% applying the exchange rate of the previous year. In euro, STADA recorded even more significant sales growth of 19% to EUR 64.8 million (1-3/2011: EUR 54.5 million), to which a positive currency effect of the Russian ruble also contributed. May 10, 2012 STADA The Health Company Page 6 of 9
7 With generics, the Group recorded strong sales growth in Russia of 18% to EUR 28.0 million (1-3/2011: EUR 23.7 million), so that their share of STADA s sales achieved in the Russian market amounted to 43% (1-3/2011: 44%). Sales of branded products rose significantly by 19% to EUR 36.3 million (1-3/2011: EUR 30.4 million) and thereby to 56% of STADA s sales in Russia (1-3/2011: 56%). In financial year 2012, STADA expects further strong sales growth in local currency in Russia with operating profitability above Group average. The sales and earnings contributions of STADA s business in both Russia as well as at the Group level will remain significantly affected by the development of the currency relation of the Russian ruble to the euro. Product Development Research and development costs amounted to EUR 13.1 million in the first three months of the current financial year (1-3/2011: EUR 11.8 million). Since STADA does not carry out any research into new active pharmaceutical ingredients due to its business model, it is only a matter of development costs. In addition, the Group capitalized development costs for new products in the amount of EUR 3.3 million in the first quarter of 2012 (1-3/2011: EUR 2.6 million). Overall, STADA launched 181 individual products worldwide in the reporting quarter (1-3/2011: 147 product launches) in individual national markets. As concerns Group-owned production capacities, we have achieved significant growth in the context of STADA build the future over the recent years with the introduction of previously externally awarded production orders to in-house production as well as with the preference for in-house production of new products. In the area of product development, we were able to conclude contracts to award a total of four projects to external developers in India in the current financial year, positively commented Dr. Axel Müller, STADA's Chief Production and Development Officer. May 10, 2012 STADA The Health Company Page 7 of 9
8 In view of the product pipeline, which remains well-filled, the Executive Board expects an ongoing flow of new product launches to continue in the future, with a focus on generics in EU countries. Outlook The Executive Board confirms the outlook for the future development of the STADA Group already given at the beginning of the year. Thereby, sales and earnings development of the Group will indeed continue to be characterized by partially stimulating, but also in part very challenging framework conditions in the various national markets in which STADA is active. In the overall assessment of opposing influence factors, the Executive Board, from today s perspective, nevertheless expects a further clear increase in Group sales for 2012, in particular with the inclusion of the recent acquisitions of the current financial year. Here, according to the estimation of the Executive Board, the Branded Products segment is expected to grow at a disproportionate rate in 2012, so that the share of the generally higher margin branded products in Group sales will thereby continue to grow. In order to strengthen the mid and long-term earnings potential, STADA will continue to implement the Group-wide cost efficiency program STADA build the future scheduled for the period of 2010 to Thereby, the expected planned projectrelated costs will continue to be reported as one-time special effects according to the progress of the project in each case; this also includes the one-time burden incurred from the sale of the factory in Ireland in the first quarter of 2012, as well as potential burdens in the higher single-digit million euro area from the evaluated sales of two production facilities in Russia. Despite these earnings burdening one-time special effects from the further implementation of the "STADA build the future" program, the Executive Board expects a significant increase in reported net income for 2012 as compared to The STADA Executive Board also expects continued growth in the key earnings figures adjusted for one-time special effects in the Group for 2012 and also sees, from today's perspective, the opportunity for an increase in the high single-digit percent area in May 10, 2012 STADA The Health Company Page 8 of 9
9 EBITDA adjusted for one-time special effects for This means that record results are once again targeted for these key figures in Furthermore, the Executive Board affirms its long-term prognosis envisaged for 2014, according to which Group sales of approx. EUR 2.15 billion, at an adjusted level, EBITDA of approx. EUR 430 million and net income of approx. EUR 215 million should be reached. The Group's recent acquisitions, which STADA finances organically, i.e. without a capital increase, give the Executive Board a high level of confidence that these long-term growth targets will, at a minimum, be reached despite the operating challenges that still remain in individual national markets. Additional information: STADA Arzneimittel AG / Corporate Communications / Stadastraße 2 18 / D Bad Vilbel / Tel.: +49 (0) / Fax: +49 (0) / communications@stada.de. Or visit us in the Internet at May 10, 2012 STADA The Health Company Page 9 of 9
Corporate News. November 11, 2010 STADA The Health Company Page 1 of 11
Corporate News STADA: Group sales increased in 1-9/2010 adjusted EBITDA went up considerably high burdening one-time special effects confirmation of outlook for 2010 Important items at a glance Group sales
More informationSTADA Group results 2006 confirm eleventh record year optimistic outlook
Corporate News STADA Group results 2006 confirm eleventh record year optimistic outlook Important items at a glance 2006: STADA s eleventh record year in a row All preliminary financial figures (ad hoc
More informationSTADA: Growth after nine months of 2006: Sales +18%, adjusted net income +27%
Corporate News STADA: Growth after nine months of 2006: Sales +18%, adjusted net income +27% Important items at a glance Nine-month figures 2006 confirm sustainable growth: o Group sales EUR 870.3 million
More informationSTADA: Strong growth continues in H1/2007 sales +27%, net income +38%
Corporate News STADA: Strong growth continues in H1/2007 sales +27%, net income +38% Important items at a glance Group sales increase by 27% to EUR 737.4 million in H1/2007 Net income grows by 38% to EUR
More informationSTADA: Strong growth in 1-9/2007: Sales +25%, operating profit +41%
Corporate News STADA: Strong growth in 1-9/2007: Sales +25%, operating profit +41% STADA interim report after 9 months of 2007: Important items at a glance Strong operative growth continues as expected
More informationSTADA: Strong growth continues in H1/2006 sales +18%, net income +32%
Corporate News STADA: Strong growth continues in H1/2006 sales +18%, net income +32% Important items at a glance As expected, Group sales increases strongly in H1/2006 by +18% to EUR 580.0 million Net
More informationSTADA KEY FIGURES. 02 STADA Key Figures. 6 months 2015 Jan. 1 June 30 ± % 6 months 2016 Jan. 1 June 30. Key figures for the Group in million
02 STADA Key Figures STADA KEY FIGURES Key figures for the Group in million 6 months 2016 Jan. 1 June 30 6 months 2015 Jan. 1 June 30 ± % Group sales 1,034.7 1,025.9 +1% Generics (core segment) 603.8 615.3-2%
More informationInterim Report on the First Three Months 2017 Brands for People
Interim Report on the First Three Months 2017 Brands for People 02 STADA Key Figures STADA KEY FIGURES Key figures for the Group in million 3 months 2017 Jan. 1 Mar. 31 3 months 2016 Jan. 1 Mar. 31 ± %
More informationInvestor News May 3, 2018
Investor News May 3, 2018 STADA with solid business development in the first quarter of 2018 STADA had a good start to the year Both generics and branded products contribute to higher adjusted Group sales
More informationSTADA Arzneimittel AG in the first six months of 2001: Successful course continues. Sales +14%; EBITDA +30%; earnings per share (DVFA) +27%
Press Release STADA Arzneimittel AG in the first six months of 2001: Successful course continues Strong earnings growth: Sales +14%; EBITDA +30%; earnings per share (DVFA) +27% Market capitalization as
More informationKey figures for the Group in million Q1/2018 Q1/2017 ± %
02 STADA Key Figures STADA KEY FIGURES Key figures for the Group in million Q1/2018 Q1/2017 ± % Group sales 558.1 566.3-1% Generics 326.8 325.9 0% Branded Products 231.3 240.4-4% Operating profit 87.9
More informationInterim Report on the First Six Months and the Second Quarter of 2017 Brands for People
Interim Report on the First Six Months and the Second Quarter of 2017 Brands for People 02 STADA Key Figures STADA KEY FIGURES Key figures for the Group in million Q2/2017 1) Q2/2016 ± % H1/2017 1) H1/2016
More informationKey figures for the Group in million Q2/2018 Q2/2017 ± % H1/2018 H1/2017 ± %
02 STADA Key Figures STADA KEY FIGURES Key figures for the Group in million Q2/2018 Q2/2017 ± % H1/2018 H1/2017 ± % Group sales 579.4 576.9 0% 1,137.5 1,143.2-1% Generics 345.5 348.5-1% 672.4 674.4 0%
More informationMr. Chairman, Ladies and Gentlemen, Dear shareholders,
Page 1 Chart 1: Ordinary Annual General Meeting Mr. Chairman, Ladies and Gentlemen, Dear shareholders, I am delighted to welcome you here today on behalf of the entire Executive Board. Thank you for responding
More informationT H E H E A LT H C O M P A N Y A N N U A L R E P O R T
THE HEALTH COMPANY ANNUAL REPORT 2001 STADA 2001 Key Figures for the Group Key figures for the Group in e million 2001 2000 ± Sales 537.8 467.2 +15% EBITDA 74.9 54.2 1) +38% Profit before taxes 47.8 33.4
More informationHenkel reports strong performance in third quarter
Investor Relations News November 12, 2013 Significant increase in earnings and profitability Henkel reports strong performance in third quarter Solid organic sales growth of 4.2% Sales impacted by foreign
More informationHenkel records strong performance in second quarter
Press Release August 8, 2013 2013 guidance confirmed Henkel records strong performance in second quarter Sales rise 1.9% to 4,286 million euros (organic: +4.0%) Adjusted operating profit: +8.2% to 660
More informationInvestor Relations News May 8, Strong earnings growth in first quarter. Henkel reconfirms 2013 guidance
Investor Relations News May 8, 2013 Henkel reconfirms 2013 guidance Strong earnings growth in first quarter Sales rise 0.6% to 4,033 million euros (organic: +2.5%) Adjusted operating profit: +8.9% to 600
More informationGEA announces figures for the third quarter
Quarterly Statement July 1 to September 30, GEA announces figures for the third quarter GEA s order intake in the third quarter of was EUR 1,084 million. The development was impacted by delays in the awarding
More informationKey figures for the Group in million 9M/2018 9M/2017 ± %
02 STADA Key Figures STADA KEY FIGURES Key figures for the Group in million 9M/2018 9M/2017 ± % Group sales 1,708.3 1,709.3 0% Generics 1,009.9 1,001.0 +1% Branded Products 698.4 708.3-1% Operating profit
More informationGEA announces figures for the first quarter
Quarterly Statement January 1 to March 31, GEA announces figures for the first quarter Thanks to robust growth in small and mid-sized orders, GEA s order intake in the first quarter of almost matched the
More informationStröer continues on a successful course in the third quarter and expects more profitable growth in 2018
PRESS RELEASE Ströer continues on a successful course in the third quarter and expects more profitable growth in 2018 Ströer anticipating consolidated revenue of EUR 1.5b and operational EBITDA of EUR
More informationHerford Half-year Report 2016/17
AHLERS AG Herford Half-year Report 2016/17 2 AHLERS AG HALF-YEAR REPORT 2016/17 (December 1, 2016 to May 31, 2017) BUSINESS PERFORMANCE IN THE FIRST SIX MONTHS OF FISCAL 2016/17 H1 2016/17 - Highlights
More informationAnnual 2014 Report. Insert URL here.
Annual 2014 Report Danfoss Financial lorem highlights ipsum in dolorem EURO 2014 Insert URL here www.danfoss.com FIND US HERE: DANFOSS.COM www.facebook.com/danfoss www.twitter.com/danfoss http://plus.google.com/+danfoss
More informationH1/Q Financial Results
H1/Q2 2017 Financial Results 1 Forward-looking statement The statements on the future in this presentation, including expected sales and earnings, are associated with risks and uncertainties and may be
More informationStatement by Kasper Rorsted Chairman of the Management Board Conference-Call May 7, 2015, a.m.
Statement by Kasper Rorsted Chairman of the Management Board Conference-Call May 7, 2015, 10.30 a.m. Welcome to our conference call. Earlier this morning you received our press release and quarterly report
More informationWelcome to the conference call Dürr AG. Results January-March 2007 Dürr Group
Welcome to the conference call Dürr AG Results January-March 2007 Dürr Group Stuttgart, May 10, 2007 Disclaimer This presentation has been prepared independently by Dürr AG ( Dürr ). The presentation contains
More informationStrong performance in a challenging environment
Investor Relations News February 20, 2014 Henkel delivers on 2013 financial targets Strong performance in a challenging environment Solid organic sales growth of 3.5% Sales impacted by foreign exchange
More informationStröer Media AG: Positive business performance in the first quarter
PRESS RELEASE Ströer Media AG: Positive business performance in the first quarter Consolidated revenue up 5.8% to EUR 125.5m 5.9% organic growth Operational EBITDA increases by 45.6% to EUR 13.5m Clear
More informationHerford Interim Report Q3 2014/15
AHLERS AG Herford Interim Report Q3 2014/15 AHLERS AG INTERIM REPORT Q3 2014/15 (December 1, 2014 to August 31, 2015) BUSINESS PERFORMANCE IN THE FIRST NINE MONTHS OF FISCAL 2014/15 -- Premium brands
More informationUlf Santjer, Tel Dieter Bock, Tel
For immediate release MEDIA CONTACT: INVESTOR CONTACT: Ulf Santjer, Tel. +49 9132 81 2489 Dieter Bock, Tel. +49 9132 81 2261 Herzogenaurach, Germany, February 10, 2006 PUMA AG announces its consolidated
More informationMETRO QUARTERLY STATEMENT 9M/Q3 2017/18
CONTENT 2 Overview 4 Sales, earnings and financial position 5 Earnings position of the sales lines 5 8 Real 9 Others 10 Outlook 11 Store network 12 Income statement 13 Balance sheet 15 Cash flow statement
More informationDaimler accelerates along its course strong growth in revenue, earnings and cash flow in third quarter
Investor Relations Release Daimler accelerates along its course strong growth in revenue, earnings and cash flow in third quarter October 23, 2014 Unit sales 7% above prior-year level at 637,400 vehicles
More informationAHLERS AG, HERFORD Interim Report Q3 2013/14
AHLERS AG, HERFORD Interim Report Q3 2013/14 2 INTERIM REPORT Q3 2013/14 AHLERS AG INTERIM REPORT Q3 2013/14 (December 1, 2013 to August 31, 2014) BUSINESS PERFORMANCE IN THE FIRST NINE MONTHS OF FISCAL
More information1 st Quarter, 2014 Danfoss delivers strong first quarter
1 st Quarter, 2014 Danfoss delivers strong first quarter www.danfoss.com www.danfoss.com Danfoss at a glance Danfoss is a world-leading supplier of technologies that meet the growing need for food supply,
More informationInterim Management Statement Q3 YTD 2018
Interim Management Statement Q3 YTD 2018 November 7, 2018 Release no. 20/2018 Columbus delivers 52% growth in revenue In the first three quarters of 2018 Columbus delivers revenue growth of 52% and increases
More informationDaimler: Net profit almost doubles in first quarter of 2014
Investor Relations Release Daimler: Net profit almost doubles in first quarter of 2014 April 30, 2014 Total unit sales of 565,800 vehicles at record level in first quarter Revenue up by 13% to 29.5 billion
More informationHeidelbergCement reports preliminary figures for Q4 and full year 2013
HeidelbergCement reports preliminary figures for Q4 and full year 2013 Press release Q4 2013: Revenue stable at 3.5 billion; like for like*: +6.9% Operating income improved by 2.4% to 463 million; like
More informationGERRY WEBER International AG Report on the first three months of 2007/2008. Report on the three-month period ended 31 January 2008
GERRY WEBER International AG Report on the first three months of 2007/2008 Report on the three-month period ended 31 January 2008 WKN: 330 410 ISIN: DE0003304101 The share In the first quarter of 2007/2008
More informationQ2 & H1 FINANCIAL RESULTS. July
Q2 & H FINANCIAL RESULTS July 29 205 Forward Looking Statements This Presentation may include forward-looking statements. Forward-looking statements are statements regarding or based upon our management
More informationQ Quarterly Statement as at September 30, 2016
Q1 3 2016 Quarterly Statement as at September 30, 2016 Sales revenues increase by 11 % to 1.7 billion Earnings (EBIT) up 6 % to 276 million Outlook for the financial year 2016 reaffirmed: Organic and acquisition-based
More informationKey figures for the Group in million ± %
02 STADA Key Figures STADA KEY FIGURES Key figures for the Group in million 2017 2016 ± % Group sales 2,313.9 2,139.2 +8% Generics 1,361.7 1,280.7 +6% Branded Products 952.2 858.5 +11% Operating profit
More informationBilfinger Berger: Entering new growth phase
Bilfinger Berger: Entering new growth phase Roadshow London, Roland Koch, CEO Andreas Müller, Head of Corporate Accounting and Investor Relations Agenda 1. Bilfinger Berger Overview 2. Preliminary figures
More informationHannover Re beats Group net income guidance for 2017 and is highly satisfied with treaty renewals as at 1 January 2018
Hannover Re beats Group net income guidance for 2017 and is highly satisfied with treaty renewals as at 1 January 2018 Hannover, 7 February 2018: As part of its reporting on the outcome of the treaty renewals
More informationBAWAG GROUP REPORTS STRONG H PROFIT BEFORE TAX OF EUR 251 MILLION
BAWAG GROUP REPORTS STRONG H1 PROFIT BEFORE TAX OF EUR 251 MILLION Profit before tax of EUR 251 million, +3% versus prior year Return on tangible equity (@12% CET1) of 18.3% Core revenues of EUR 502 million,
More informationHenkel continues its strong business performance in the third quarter
News Release November 8, 2016 Guidance for 2016 confirmed Henkel continues its strong business performance in the third quarter Sales at 4,748 million euros: organic +2.8% (nominal: +3.4%) Emerging markets
More informationBMW Group Corporate and Governmental Affairs
3 August, 2010 - Please check against delivery - Statement by Dr. Friedrich Eichiner Member of the Board of Management of BMW AG, Finance 3 August 2010, 10:00 a.m. Ladies and Gentlemen, Good morning from
More informationQuarterly Financial Report
3/2011 Quarterly Financial Report First nine months of 2011 Sales up by more than 25 % EBIT at 2.8 million EBIT margin over 10 % Earnings per share at 0.39 QUARTERLY FINANCIAL REPORT 3/2011 Dear Shareholders,
More informationPress Release December 15, 2016
ISRA VISION AG: 2015/2016 financial year Strong, double-digit growth for the full year: Revenues +15 %, EBT +15 % ISRA with high growth rates in the 2015 / 2016 financial year Revenues and EBT exceed forecast
More informationHerford Interim Report Q1 2014/15
AHLERS AG Herford Interim Report Q1 2014/15 AHLERS AG INTERIM REPORT Q1 2014/15 (December 1, 2014 to February 28, 2015) BUSINESS PERFORMANCE IN THE FIRST THREE MONTHS OF FISCAL 2014/15 -- 7 percent decline
More informationStröer Media SE posts record-high earnings in fiscal year 2014
PRESS RELEASE Ströer Media SE posts record-high earnings in fiscal year 2014 Revenue for the year climbs to EUR 721.1m Operational EBITDA rises to EUR 148.1m in 2014, up 25% on the prior year Adjusted
More informationCENIT AG Systemhaus. Industriestraße D Stuttgart Tel: Fax: Internet:
3 Months Report 2008 CENIT AG Systemhaus Industriestraße 52-54 D-70565 Stuttgart Tel: + 49 711 7825-30 Fax: + 49 711 7825-4000 Internet: http://www.cenit.de Investor Relations: ISIN:DE0005407100 Fabian
More informationInterim announcement 1st to 3rd quarter 2015
Interim announcement 1st to 3rd quarter 2015 Danfoss at a glance Danfoss engineers technologies that enable the world of tomorrow to do more with less. We meet the growing need for infrastructure, food
More informationPress Release HUGO BOSS First Half Year Results HUGO BOSS accelerates growth in second quarter of 2015
Press Release HUGO BOSS First Half Year Results HUGO BOSS accelerates growth in second quarter of Sales rise by 16% in reporting currency and 7% currency-adjusted 6% increase in retail comp store sales
More informationBasware expects its net sales and operating profit (EBIT) for 2015 to grow compared to 2014.
Interim Report 1 (21) BASWARE INTERIM REPORT JANUARY 1 SEPTEMBER 30, 2015 (IFRS) SUMMARY Revenue developed favourably with key markets growing 95 percent January September 2015: - Net sales EUR 104 200
More informationfor the 1st Quarter from January 1 to March 31, 2017
Quarterly STATEMENT for the 1st Quarter from January 1 to March 31, 2017 Wherever you go. gigaset 1 st Quarterly statement 2017 key figures millions 01/01/-03/31/2017 01/01/-03/31/2016 1 Consolidated revenues
More informationPress release Regulated information 2015 results Under embargo until Thursday 25 February 2016 at 7:15 a.m. CET
Under embargo until Thursday 25 February 2016 at 7:15 a.m. CET Deceuninck 2015: Solid growth. Sales: 644.5m (+16.6%), EBITDA: 54.4(+54%) and net result: 13.3m (+ 27%) Growth driven by successful integration
More informationABG Sundal Collier Small & Mid-Cap Seminar. 16 April 2015
ABG Sundal Collier Small & Mid-Cap Seminar 16 April 2015 2 Forward-looking statement The statements on the future in this presentation, including expected sales and earnings, are associated with risks
More informationHenkel Roadshow Q November, 2014
Henkel Roadshow Q3 2014 November, 2014 Disclaimer This information contains forward-looking statements which are based on current estimates and assumptions made by the corporate management of Henkel AG
More informationInterim report as per March 31, 2017
Interim report as per March 31, 2017 Key financial figures Sales (in keur) Operating income (in keur) Financial income (in keur) 2013 7,978 2014 11,063 2015 13,659 2016 14,425 2017 14,795 3M 2017 14,795
More informationLinde Group. First Nine Months 2004 Conference Call. November 11, Dr. Peter Diesch, CFO
Linde Group First Nine Months 2004 Conference Call November 11, 2004 Dr. Peter Diesch, CFO Linde Group Key Facts Significant increase in sales and EBITA EPS of 1.28 (2003: 0.63), excl. Goodwill 2.11 (2003:
More information2011QUARTERLY STATEMENT AS OF SEPTEMBER 30
2011QUARTERLY STATEMENT AS OF SEPTEMBER 30 To our Shareholders Ernst Homolka, CEO Dear shareholders, ladies and gentlemen, The Nemetschek Group continues its profitable growth course. In the first nine
More informationThe analysis and outlook of the current macroeconomic situation and macroeconomic policies
The analysis and outlook of the current macroeconomic situation and macroeconomic policies Chief Economist of the Economic Forecast Department of the State Information Centre Wang Yuanhong 2014.05.28 Address:
More informationGERRY WEBER International AG Interim report Q2 2010/2011. Report on the six-month period ended 30 April 2011 WKN: ISIN: DE
GERRY WEBER International AG Interim report Q2 2010/2011 Report on the six-month period ended 30 April 2011 WKN: 330 410 ISIN: DE0003304101 The GERRY WEBER share Gaining roughly 27 percent, the GERRY WEBER
More informationFinancial Highlights in EURO Danfoss ready for the future
Financial Highlights in EURO Danfoss ready for the future www.danfoss.com www.danfoss.com Danfoss at a glance Danfoss is a world-leading supplier of technologies that meet the growing need for food supply,
More informationInterim Report Q3 2018
Interim Report Q3 2018 4 A KEY FIGURES Q3 Key Figures Group amounts in millions Q3 2018 Q3 2017 % change Revenue 40,211 40,745 2-1 1 Europe 16,151 16,682-3 thereof Germany 5,931 5,803 +2 NAFTA 11,743 11,525
More information+ 6 % Earnings (EBIT) increase to 297 million
Quarterly statement as at September 30, 2018 Q3 / 2018 Sales revenues up by 5 % to 1,953 million + 6 % Earnings (EBIT) increase to 297 million (including one-off effect) Outlook updated: Sales revenue
More informationNotification of Major Holdings. 1. Details of issuer. STADA Arzneimittel AG Stadastraße Bad Vilbel Germany. 2. Reason for notification
DGAP Voting Rights Announcement: STADA Arzneimittel AG STADA Arzneimittel AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide
More informationN O R M A G R O U P S E
NORMA GROUP SE Overview of Key Figures Q3 2017 1 Q3 2016 1 Q1 Q3 2017 1 Q1 Q3 2016 1 Order situation Oder book (Sep 30) EUR millions 322.7 282.7 Income statement Revenue EUR millions 244.4 216.6 763.4
More informationP R E S S R E L E A S E
P R E S S R E L E A S E from ASSA ABLOY AB (publ) 27 April 2004 No. 5/04 ASSA ABLOY Q1: ORGANIC GROWTH AND IMPROVED MARGINS IN ALL DIVISIONS Sales in the first quarter increased organically by 3% to SEK
More informationOrders received in CHF million. Sales in CHF million. EBIT in CHF million. Capital expenditures in CHF million
Semi-Annual Report 2 Rieter. Semi-Annual Report. Rieter at a glance Rieter at a glance Orders received in Sales in EBIT in Capital expenditures in HY1 15 HY2 15 HY1 16 HY1 15 HY2 15 HY1 16 HY1 15 HY2 15
More informationCCH Annual General Meeting CEO presentation 11 June 2018
Zoran Bogdanovic CEO Coca-Cola HBC AG Good morning. Thank you for joining our Annual General Meeting. Before we get started, I would like to remind everyone that this presentation contains various forward
More informationFY 2017 Results. March 6, 2018
FY 2017 Results March 6, 2018 Forward looking statements This Presentation may include forward-looking statements. Forward-looking statements are statements regarding or based upon our management s current
More informationNine-month figures for 2017: Sartorius continues to grow profitably in a challenging environment
Nine-month figures for : Sartorius continues to grow profitably in a challenging environment Group revenue up 8.6%; despite unfavorable currency effects, earnings 1 up 7.3% The Lab Products & Services
More informationHenkel achieves new highs in sales and earnings
News Release February 22, 2018 Strong performance in fiscal year 2017 Henkel achieves new highs in sales and earnings Sales increase to 20,029 million euros, first time above 20 bn euros: nominal growth
More informationHeidelbergCement reports results for the first quarter of 2017
10 May 2017 HeidelbergCement reports results for the first quarter of 2017 Italcementi acquisition strengthens sales volumes, revenue and result Sales volumes: 28 million tonnes of cement (+58%); 61 million
More informationPlease note: this is a translation; only the German version of this news release is legally binding.
August 22, 2006 Please note: this is a translation; only the German version of this news release is legally binding. Vienna Insurance Group (Wiener Städtische Group) in the first half of 2006 (IFRS figures):
More informationReport on the first half of fiscal 2009
Report on the first half of fiscal 2009 Table of Contents 3 Letter to the Shareholders 4 Management Report 8 Interim Financial Statement 9 Consolidated income statement for the period 01.01.2009 30.06.2009
More informationInterim Report January-June Fortum Corporation 20 July 2016
Interim Report January-June 2016 Fortum Corporation 20 July 2016 Disclaimer This presentation does not constitute an invitation to underwrite, subscribe for, or otherwise acquire or dispose of any Fortum
More informationThe Health Company. Annual Report 2005
The Health Company 2 005 Annual Report 2005 813.5 87.8 1,022.1 127.1 Group sales in million Operating profit in million 2004 2005 2004 2005 Key figures for the Group in million 2005 2004 ±% Sales 1,022.1
More informationGrowth and Margin Expansion Continues
Brussels, May 12, 2006-1/7 Growth and Margin Expansion Continues InBev (Euronext: INB), the world s leading brewer by volume, announced today its results for the first quarter of 2006 (1Q06): Balanced
More informationHalf-year report July 25, 2018
Half-year report July 25, 218 1 Agenda Highlights of January-June 218 April-June 218 January-June 218 Segments Mail, Parcel and Logistics Services Itella Russia OpusCapita Financial targets Outlook 218
More informationJanuary 1 to March 31. Interim Report January to March 2004
25 26 27 January 1 to March 31 Interim Report 24 First Quarter 24 Linde Financial Highlights 24 23 Change Year 23 Share Closing price 43.9 29.15 47.8% 42.7 3 month high 45.9 36.69 25.1% 43.4 3 month low
More informationFY 2017 FINANCIAL RESULTS. Milan February 27 th, 2018
FY 2017 FINANCIAL RESULTS Milan February 27 th, 2018 1 AGENDA FY 2017 Highlights o o Group overview Results by business Financial results Appendix 2 Key Achievements of 2017 General Cable Acquisition Leadership
More informationProSiebenSat.1 continues profitable growth in Q1 2014
Press Release ProSiebenSat.1 continues profitable growth in Q1 2014 Page 1 Consolidated revenues up 3.3 % to EUR 581.1 million Recurring EBITDA up strongly by 9.5 % to EUR 140.1 million Underlying net
More informationCorporate Development and Strategy, Hartmut Ostrowski Annual Press Conference, Bertelsmann AG, March 24, 2009 in Berlin
Corporate Development and Strategy, Hartmut Ostrowski Annual Press Conference, Bertelsmann AG, March 24, 2009 in Berlin Corporate Development and Strategy Hartmut Ostrowski Bertelsmann 2008 1 Solid operating
More informationSiltronic successfully closes the financial year 2018 and plans to pay a dividend of EUR 5.00 per share
Press release Siltronic AG Hanns-Seidel-Platz 4 81737 Munich www.siltronic.com Siltronic successfully closes the financial year and plans to pay a dividend of EUR 5.00 per share - Sales up to EUR 1,456.7
More informationCourse of Business and Economic Position
0 Course of Business and Economic Position Group Overview of 07 Group net sales increase slightly by.0% to 5.3 billion Healthcare and Life Science deliver organic sales growth EBITDA pre of 4.4 billion
More informationFortum intends to become a major shareholder in Uniper
A powerful combination to drive European energy transition Fortum intends to become a major shareholder in Uniper 27 September 2017 Disclaimer This presentation is neither an offer to purchase, underwrite,
More informationQuarterly Statement as of September 30, 2017
Quarterly Statement as of September 30, 2017 7 Group Key Figures in millions Q3/2017 Q3/2016 Change 9M/2017 9M/2016 Change Group Segments 3) Revenues Liquidity and financial position Share-related key
More informationPress Release HUGO BOSS First Half Year Results HUGO BOSS steps up growth pace
Press Release HUGO BOSS First Half Year Results HUGO BOSS steps up growth pace Strong own retail performance supports 8% growth of Group sales in the second quarter Double-digit increase in profit Rise
More informationFOR THE FIRST QUARTER OF
Fall in demand continues As expected the profit after tax of 16.2 million remained at the level of the fourth quarter of 2008 Cost-cutting measures are taking effect Free cash flow rose to 39 million Group
More informationVBH Holding AG creates a solid basis for further growth with operating profits for 2010
VBH Holding AG creates a solid basis for further growth with operating profits for 2010 Korntal-Münchingen, March 31, 2011 After the economydriven setbacks in the previous year, in 2010 VBH Holding AG,
More informationHDI Global SE improves underwriting result
HDI Global SE improves underwriting result Gross written premiums at EUR 4.3 (2015: 4.3) billion EBIT rises by 42 percent to EUR 296 (208) million Group net income increases by 86 percent to EUR 236 (127)
More information+2 % Earnings (EBIT) increase
Statement as at September 30 Q3Quarterly 2017 Sales revenues rise by 9 % to 1,862 million +2 % Earnings (EBIT) increase Earnings outlook adjusted to 281 million Content FUCHS at a glance 03 Business development
More informationHenkel reports sales and earnings at record levels
News Release February 23, 2017 Strong performance in fiscal year 2016 Henkel reports sales and earnings at record levels Sales: +3.5% to 18,714 million euros (organic: +3.1%) Emerging markets sales growth:
More informationVERBAND DER CHEMISCHEN INDUSTRIE e.v.
VERBAND DER CHEMISCHEN INDUSTRIE e.v. Statement to the press on the business situation of the German chemical industry Mr Marijn Dekkers President of Verband der Chemischen Industrie (VCI) 9 December 2015,
More informationPress Release May 31, 2017
ISRA VISION AG: 1st half year 2016 / 2017 A further step to 150 +: Revenues and EBT each grow by +11% Double-digit growth in the first six months ISRA continues growth path with high order backlog Revenues
More informationSuccessful Start to the Year by the K+S Group
Kassel, Germany, 12 May 2015 Q1 2015 quarterly financial report Successful Start to the Year by the K+S Group Revenues up 16% to 1.4 billion Salt business very strong in first quarter Price recovery continues
More information9 month statement 01 April 31 December 2013 Bastei Lübbe AG Cologne
9 month statement 01 April 31 December 2013 Bastei Lübbe AG Cologne 2 Index Interim management report 3 Interim financial statements 8 Statements of financial position 9 Profit and loss statement 10 Statement
More information